Elite Pharmaceuticals, Inc. Reports Financial Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015

Revenues increase by 8%

Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST

NORTHVALE, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP ), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter of fiscal year 2015 ended September 30, 2014.

Consolidated revenues were $1.3 million for the quarter, an increase of approximately 8% over consolidated revenues for the comparable quarter of the prior year. Quarterly revenues also increased by 8% when compared to the prior quarter. Revenues for the six months ended September 30, 2014 were $2.4 million, an increase of 29% over revenues for the comparable period of the prior year. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.

Development of our abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $3.6 million in clinical trials and other product development activities. During the first six months of our fiscal year, we have invested a total of $7.5 million in product development including successful completion of the human abuse liability study for ELI-200 and other development activities related to ELI-200 as well as Elite's other abuse-deterrent opioid products. Elite will provide an update on development activities during the conference call.

During the quarter, Elite also retired the NJEDA Series B 9% bonds and became current with all NJEDA Series A bonds monetary obligations.

Nasrat Hakim, CEO of Elite commented, "This has been another positive quarter for Elite. Our generic products continue to grow and we expect to launch additional generic products later this fiscal year. These generic products continue to be an important piece of Elite's growth strategy. We, of course, also continue to diligently pursue development of our abuse-deterrent products, and we have an FDA meeting regarding ELI-200 on November 17 th . I look forward to providing an update on this meeting for you during our conference call on the 19 th . ELI-200 is expected to be the first abuse-deterrent product filed with the FDA by Elite."

The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

To access the conference call:

Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840

A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 3, 2014 by dialing:

Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840

The financial statements can be viewed in Elite's Quarterly Report on Form 10-Q at: http://www.elitepharma.com/sec_filings.asp .

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse-deterrent opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Epic Pharma for the manufacturing and distribution of eleven approved products pending manufacturing site transfer, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 www.elitepharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 147

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 115

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 168

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 158

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 54

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 68

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 124

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Impressive Q3 2025 Performance Review

Updated Category News Views 281

Hepsiburada Reports Significant Gains in Q3 2025 Hepsiburada, officially known as D-MARKET Electronic Services & Trading (NASDAQ: HEPS), has unveiled robust financial results for the third quarter of 2025. The Turkish e-commerce giant reported an impressive increase in gross merchandise value (GMV) and revenue, highlighting the company's operational resilience in a...

Continue Reading
Fulcrum Therapeutics Faces Challenges Amid Sickle Cell Trials

Updated Category News Views 212

Market Moves and Stock Reactions So, let’s get straight to the meat of it. Fulcrum Therapeutics Inc. (NASDAQ:FULC) took a nosedive recently—down about 10%—right after they dropped the latest news on their Phase 1b trial for pociredir aimed at treating sickle cell disease. Stock fell to around $9.80, and honestly, if you're still holding shares, well, it's time to...

Continue Reading
SBM Offshore's Share Repurchase Program Insights and Updates

Updated Category News Views 215

Overview of SBM Offshore’s Share Repurchase Program SBM Offshore has recently conducted a significant share repurchase program amounting to EUR141 million (approximately US$150 million). This initiative began on April 24, 2025, and aims to reduce share capital while also supporting management and employee share programs. The program has been designed to both enhance...

Continue Reading
Plymouth Industrial REIT Responds to Acquisition Proposal

Updated Category News Views 212

Plymouth Industrial REIT Receives Unsolicited Acquisition Proposal Plymouth Industrial REIT, Inc. (NYSE: PLYM), a leader in the industrial real estate sector, recently attracted attention with an unsolicited and non-binding acquisition proposal. This proposal comes from Sixth Street Partners, LLC, and suggests a price of $24.10 per share for all outstanding shares of the...

Continue Reading
Middlefield Canadian Income PCC AGM Results Breakdown

Updated Category News Views 230

Overview of the AGM Results for Middlefield Canadian Income PCC Middlefield Canadian Income PCC (the "Company") and Middlefield Canadian Income - GBP PC (the "Cell") have recently concluded their annual general meeting, a significant event that spotlighted the Company's journey and future direction. Conducted with transparency and diligence, this meeting has underscored...

Continue Reading